Amplia Therapeutics Limited
ATX.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$53.9M
Close$
$0.06
46.7% downside
Current Fair Value
46.7% downsideOvervalued by 46.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $53.90 Million |
|---|---|
| Enterprise Value | $26.33 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.02 |
| Beta | -0.4 |
| Outstanding Shares | 513,071,629 |
Return
| Return on Equity | -35.68% |
|---|---|
| Return on Assets | -33.98% |
| Return on Invested Capital | -50.14% |
Valuation & Multiples
| P/E Ratio | -6.29 |
|---|---|
| PEG | 107.1 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6.96 |
| Enterprise Value to EBIT | -1.32 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
November 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Amplia Therapeutics Limited
8 employees
CEO: Christopher J. Burns Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an i...